^
3ms
New P3 trial
|
Pegylated rhG-CSF (mecapegfilgrastim)
12ms
Application of Mecapegfilgrastim for Peripheral Blood Hematopoietic Stem Cell Mobilization in Patients With Hematologic Neoplasms and Analysis of Predictors for Poor Mobilization (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban)
To evaluate the efficacy of applying mecapegfilgrastim for peripheral blood hematopoietic stem cell (PBSC) mobilization in patients with hematologic neoplasms, and to investigate the influencing factors of PBSC collection. Furthermore, combined mobilization with plerixafor was feasible and effective. Patients with leukemia or lymphoma, anemia, and WBC<32×10 L before stem cell collection have a high probability of PBSC collection failure.
Journal
|
CD34 (CD34 molecule)
|
Pegylated rhG-CSF (mecapegfilgrastim) • plerixafor
1year
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=132, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • Pegylated rhG-CSF (mecapegfilgrastim)
over1year
Enrollment open • Combination therapy
|
CD34 (CD34 molecule)
|
cyclophosphamide • etoposide IV • Pegylated rhG-CSF (mecapegfilgrastim)
almost2years
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=132, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • Pegylated rhG-CSF (mecapegfilgrastim)
2years
New P2 trial • Combination therapy
|
CD34 (CD34 molecule)
|
cyclophosphamide • etoposide IV • Pegylated rhG-CSF (mecapegfilgrastim)